Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GENI heads into its November 4 earnings date with short sellers adding to already elevated positions, CEO sales on record, and the stock down 17% over the past month.
The short-side story is the defining feature of this stock right now. Short interest has climbed to 15.8% of the free float, up 21% over the past 30 days and now approaching the official FINRA fortnightly figure of 38.1 million shares. The build has been steady: positions were around 31 million shares in early September and have added roughly 6 million shares since. Days to cover is nearly 8, making a rapid unwind difficult. The borrow market remains loose, though. Availability is at 113% of short interest, meaning lenders still have more shares on offer than are currently borrowed. Cost to borrow, despite a 27% week-on-week jump, is still only 0.51%, near the low end of the past year's range. The short score, persistently above 71 for the past two weeks, ranks in the 6th percentile for the sector, marking this as one of the more heavily shorted names in the space.
Options positioning adds a separate wrinkle. The put/call ratio has jumped to 0.066, more than two standard deviations above its 20-day average of 0.058. That is the most defensive options posture GENI has shown in weeks, even if the absolute ratio remains low. With the stock down 17% over the past month and closing Tuesday at $6.22, market participants are paying more for downside protection heading into the print.
The Street is broadly constructive but has started trimming ambitions. Macquarie's Chad Beynon, just this week, cut his price target from $12 to $11 while keeping an Outperform rating. JP Morgan initiated coverage in late September with an Overweight and an $8 target, below where most of the street sits. The consensus remains buy, with a mean target around $10.88, implying roughly 75% upside from current levels, though that gap has historically reflected execution concerns as much as genuine conviction. The analyst rec differential factor scores in the 99th percentile, an unusually wide gap between the current price and where rated analysts think fair value lies. Valuation is not demanding on a trailing basis: the EV/EBITDA multiple is around 3.7x. EPS momentum factors rank well, in the 80th to 90th percentile on both 30-day and 90-day windows. The EPS surprise rank, though, is only in the 2nd percentile, a reminder that GENI has a poor track record of beating estimates when it matters.
The insider picture is harder to dismiss. CEO Mark Locke sold 800,000 shares across three trading days in mid-September, for proceeds of roughly $5.3 million. The CLO, Russell Thomas, sold a further 50,000 shares the same week. None of these sales were under pre-arranged 10b5-1 plans, which makes them discretionary rather than scheduled. The CFO, Bryan Castellani, exercised options in early October and withheld shares to cover taxes, a routine compensation transaction. On a 90-day net basis, insiders have disposed of 850,000 shares worth approximately $5.6 million. Locke still holds 19.4 million shares per the most recent institutional data, so his stake remains substantial. But concentrated selling at the $6.50 level, just as short interest was stepping up, is a data point worth noting.
The institutional register reflects a split picture. BlackRock added 5.1 million shares in the most recent quarter, taking its stake to 7.4%. Glenview Capital added nearly 8 million shares to cross 5%, and Hood River added 5.7 million. On the other side, Caledonia exited entirely from a prior 6.5% stake, Wellington fell from 5.6% to 0.6%, and Voss Capital trimmed below 5%. Separately, Wikipedia page view activity for GENI showed a z-score of 4.1 as of late September, well above its own 90-day average, suggesting a spike in retail attention that has not obviously translated into price support given the month's decline.
After the last quarterly print on August 6, the stock fell 8.9% in a single day and had not recovered five days later. The next report is November 4. Whether the gap between the 99th-percentile analyst recommendation spread and a short interest approaching 16% narrows or widens from here will likely depend on how much of the Media Technology growth story can offset the ongoing wind-down of the ST&S segment when GENI reports in four weeks.
See the live data behind this article on ORTEX.
Open GENI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
